Objective: To describe the profile and evolution of patients admitted for cryptococcosis. 
Introduction
Cryptococcosis is a deep mycosis caused by Cryptococcus neoformans, an encapsulated fungus [1] . It mainly affects immunocompromised individuals (human immunodeficiency virus, immunosuppressive therapy). It is one of the leading causes of death in HIV patients [1, 2] . It mostly causes meningoencephalitis, but the infection can also be pulmonary [2, 3] . Cryptococcosis is the inaugural stage of HIV infection in 29% of patients and defines the stage of Acquired Immunodeficiency Syndrome in 58% of patients [3] . Since the advent of antiretroviral therapy (ARVs), the incidence of cryptococcosis has dropped in France by 46% between 1997 and 2002. 75% of cryptococcal infections occur in patients infected with HIV. In Africa, however, this disease remains the second most fatal opportunistic infection after tuberculosis in HIVinfected individuals, affecting in some countries up to 30% of them in the absence of antiretroviral (ARVs) access [1, 4, 5] . In Senegal, cryptococcosis is the leading cause of meningitis for adults [6] .
The main goal of this study is to describe the profile and evolution of patients admitted for cryptococcosis. As secondary goals, the study aims to describe the epidemiological characteristics of these patients; the clinical, paraclinical and evolutionary aspects of cryptococcosis, and to determine factors associated with the prognosis of patients treated for cryptococcosis.
Patients and Method
Type, period, setting: This cross-sectional study was carried out from January 1, 2008 to July 31, 2012, in the infectious diseases department of the Fann National University Hospital (CHNU) in Dakar, Senegal.
Patients
Patients over 15 years diagnosed with cryptococcosis by cerebrospinal fluid (CSF), bonchoalveolar fluid (BAL) or cryptococcal antigenemia were included.
Study variables
This study variables were epidemiological (age, sex, socioprofessional status, marital status, antecedents, risk factors for HIV infection); clinical (reason for consultation or admission, consultation period, WHO classification); paraclinical (CSF analysis (cytochemistry, direct examination after staining with Indian ink, cryptococcal antigen test, culture), cryptococcal antigenemia, blood count, serum creatinine, HIV serology, TCD4 lymphocyte level, plasma viral load and brain CT scan). A compendium of the therapies used (antifungal and antiretroviral treatment) and patient outcomes (healing, sequelae, death) supplemented these data.
Statistical Analysis
The data was processed with the software EPI Info 3.3.2 (CDC Atlanta, USA). Quantitative variables were expressed as means ± standard deviation, and extremes in square brackets. Qualitative variables were reported in numbers and percentages. Comparisons of the qualitative variables used the chi-2 test, while the quantitative variables used the Student's test. The significance level for comparisons was p <0.05.
Results

Descriptive study
Fifty-seven patients were included (1.2% of admissions in the infectious diseases department), including 33 men (58%). The sex ratio (H/F) was 1.4. The mean age was 40.9 ± 9.1 years [23-65]. Thirty-three of them (57.9%) were married, including 17 polygamous and 16 monogamous; 11 patients (19.3%) were single. 25 patients were unemployed (43.9%), 15 workers or artisans (26.3%), 14 merchants (24.6%), 2 civil servants (3.5%) and 1 retired (n=1). Table 1 shows medical history, reasons for consultation, and general signs. There were 52 cases of patients with positive HIV (91.2%). The average consultation time was 44 ± 57.2 days . Table 2 is about the distribution of patients according to clinical signs. The associated pathologies were oral candidiasis (n=30, 52.6%), pleuropulmonary tuberculosis (n=13, 22.8%), chronic diarrhea (n=9; 21%), isosporosis (n=2), cryptosporidiosis (n=1) and pneumocystosis (n=1). The average CD4 was 101.29 ± 123.58 / mm 3 . This rate was less than 100 / mm 3 in 32 cases (56.1%) and between 100 and 299/mm 3 in 18 cases (31.5%). Neuromeningeal cryptococcosis was the main site (47 cases). The other locations were cutaneous (1 case) and disseminated (9 cases). In 23 cases (40.4%), a cough was associated with pulmonary condensation syndrome.
All patients were treated with oral fluconazole and no adverse effects were reported. The mean duration of treatment was 24 ± 17 days . The minimum delay between the date of diagnosis and the start of anticryptococcal treatment was 31 days. A lumbar puncture evacuator was performed in 2 cases (4%). ARV treatment was started in 20 cases (35%). Only 4 patients had received ARV treatment prior to admission. Four patients (2.3%) presented with immune reconstitution syndrome (IRIS). The delay between antifungal therapy and initiation of ARV treatment in these patients was 33 days with baseline CD4 averaging 85 ± 19/mm 3 .The mean duration of hospitalization was 23.9 ± 20.3 days [2-80].
The evolution was favorable in 22 cases (38.6%). Complications were sequelae (n=9) including blindness (n=5; 9%) and deafness (n=4; 7%); and death in 35 cases (61.4%). The causes of death were: cardiovascular collapse (26 cases), cardiorespiratory arrest (4 cases), acute respiratory distress (4 cases) and cerebral involvement (3 cases).
Analytical study (univariate analysis)
The recovery rate was statistically associated with ART use after admission and Glasgow score > 8 on admission (Table 3) .
Parameters
Recovery n (%) Death n (%) P-value [1, 7, 8] . This male predominance contrasts with the feminization of HIV infection.
Young adults are the most concerned [6, 8] . This population is the most affected by HIV infection which is the main field of cryptococcosis occurrence in our countries. Our service is only specialised for adults. However, according to data from the literature, the number of children making cryptococcosis is very low [9] . This relative resistance to infection is poorly explained since the fungus is present in the environment and children are, like adults, able to produce anti-cryptococcal antibodies. Differences in lifestyle, occupation or exposure cannot explain differences by age and sex alone. It is possible that hormonal or genetic factors come into play.
Patients with low standards of living and working in low-income occupations are the most affected in our study. This finding, often reported in Africa, reflects the socio-economic environment that is the bedrock of HIV-AIDS [1, 8] .
Neuromeningeal cryptococcosis was associated with other pathologies including tuberculosis in 13 patients. These results are consistent with those of Sow and Cameron in Dakar [6, 10] .
Oral fluconazole was the only antifungal used in our study. This molecule was used in the series of Soumaré [8] and Milongo [7] , respectively in 93% of cases in perfusion and 100% in bones. Numerous studies in recent years have noted a superiority of amphotericin B and 5-fluorocytosine over fluconazole or amphotericin monotherapy [11] [12] [13] .
The mean duration of induction therapy in our fluconazole patients was 24 days. This longer or shorter duration could be justified by the persistence of the clinical picture in our patients and the absence of CSF negativization taken after 15 days. Also, it should be noted that the difference was not significant regarding the doses of fluconazole administered in our patients.
In our series, two patients (4%) had lumbar puncture evacuation. These were patients who were suspected of persistent intracranial hypertension manifested by atrocious headache. This low rate can be justified by the weakness of our technical platform for the diagnosis of intracranial hypertension.
Twenty patients (35%) had received antiretroviral therapy. The initiation of highly active ART after the diagnosis of cryptococcosis should be early to avoid the occurrence of other opportunistic infections. Nevertheless, it must take into account the risk of IRIS [14] [15] [16] [17] . In our study, the delay between the start of antifungal therapy and antiretroviral treatment was thirty-one days. This long delay can be explained in part by the scarcity of the molecule on the market, the financial difficulties of the patient who deals with the opportunistic infection himself.
The average length of stay was 23.87 days in our series. This result corroborates that obtained by Milongo in Burkina Faso [7] . This can be explained by the fact that patients go to hospital at a fairly advanced stage of the disease, thus prolonging the duration of the treatment. Lethality was 61.4% in our series. This rate is lower than that obtained by Sow et al. in Dakar (71%), Bissagnene in Cote d'Ivoire (64.8%), [6.18] . These studies were conducted before the advent of highly active ART. In fact, Aoussi, in Abidjan, had a lower lethality (41.2%) in a study on neuromeningeal cryptococcosis and HIV in the era of ART in Cote d'Ivoire. This study was also characterized by a greater frequency of evacuation puncture [19] . Most authors emphasize that clinical improvement during cryptococcal meningitis treatment is usually slow (1 to 2 weeks). Sterility of CSF is obtained after 15 days up to 2 months [6 18 ]. Also, the average duration of CSF sterilization is shorter with amphotericin B (.15 days) + flucytsin than with fluconazole (approximately 40 days) [20] . The low standard of living of our patients for whom the cost of care is out of reach, the delayed diagnosis, our working conditions characterized by the limitation of the therapeutic means would largely explain this high mortality rate (61.4%). %) [21] .
Conclusion
Cryptococcosis remains the second most fatal opportunistic infection in HIV patients and profoundly immunocompromised. It remains a real public health problem in Africa, associated with a high lethality. Prevention, early management of HIV infection, and wider accessibility to antifungal therapies would improve management and limit the impact.
